These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 26457356)
21. Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology. Uimari O; Ahtikoski A; Kämpjärvi K; Butzow R; Järvelä IY; Ryynänen M; Aaltonen LA; Vahteristo P; Kuismin O Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2066-2075. PubMed ID: 34480341 [TBL] [Abstract][Full Text] [Related]
22. Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. Llamas-Velasco M; Requena L; Kutzner H; Schärer L; Rütten A; Hantschke M; Paredes BE; Mentzel T J Cutan Pathol; 2014 Nov; 41(11):859-65. PubMed ID: 25292446 [TBL] [Abstract][Full Text] [Related]
23. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations. Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573 [TBL] [Abstract][Full Text] [Related]
25. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276 [TBL] [Abstract][Full Text] [Related]
26. [A special uterine leiomyoma]. Brunet A; Verkarre V; Le Frère Belda MA Ann Pathol; 2020 Apr; 40(2):180-184. PubMed ID: 32192807 [TBL] [Abstract][Full Text] [Related]
27. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Alam NA; Barclay E; Rowan AJ; Tyrer JP; Calonje E; Manek S; Kelsell D; Leigh I; Olpin S; Tomlinson IP Arch Dermatol; 2005 Feb; 141(2):199-206. PubMed ID: 15724016 [TBL] [Abstract][Full Text] [Related]
28. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760 [TBL] [Abstract][Full Text] [Related]
29. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma. Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas. Ahvenainen T; Kaukomaa J; Kämpjärvi K; Uimari O; Ahtikoski A; Mäkinen N; Heikinheimo O; Aaltonen LA; Karhu A; Bützow R; Vahteristo P Am J Surg Pathol; 2022 Apr; 46(4):537-546. PubMed ID: 34678832 [TBL] [Abstract][Full Text] [Related]
31. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274 [TBL] [Abstract][Full Text] [Related]
32. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression. Anderson WJ; Tsai HK; Sholl LM; Hirsch MS Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731 [No Abstract] [Full Text] [Related]
33. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700 [TBL] [Abstract][Full Text] [Related]
34. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases. Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557 [TBL] [Abstract][Full Text] [Related]
35. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Reyes C; Karamurzin Y; Frizzell N; Garg K; Nonaka D; Chen YB; Soslow RA Mod Pathol; 2014 Jul; 27(7):1020-7. PubMed ID: 24309325 [TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and molecular characteristics of fumarate hydratase-deficient uterine smooth muscle tumors: a single-center study of 52 cases. Li H; Yang W; Tu X; Yu L; Huang D; Cheng Y; Chang B; Tang S; Ge H; Bao L; Zhou X; Bi R Hum Pathol; 2022 Aug; 126():136-145. PubMed ID: 35659509 [TBL] [Abstract][Full Text] [Related]
37. Fumarate Hydratase and S-(2-Succinyl)-Cysteine Immunohistochemistry Shows Evidence of Fumarate Hydratase Deficiency in 2% of Uterine Leiomyosarcomas: A Cohort Study of 348 Tumors. Chapel DB; Sharma A; Maccio L; Bragantini E; Zannoni GF; Yuan L; Quade BJ; Parra-Herran C; Nucci MR Int J Gynecol Pathol; 2023 Mar; 42(2):120-135. PubMed ID: 36729957 [TBL] [Abstract][Full Text] [Related]
38. The syndrome of hereditary leiomyomatosis and renal cell cancer (HLRCC): The clinical features of an individual with a fumarate hydratase gene mutation. Varol A; Stapleton K; Roscioli T Australas J Dermatol; 2006 Nov; 47(4):274-6. PubMed ID: 17034471 [TBL] [Abstract][Full Text] [Related]
39. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report. Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443 [TBL] [Abstract][Full Text] [Related]
40. Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma. Skala SL; Dhanasekaran SM; Mehra R Arch Pathol Lab Med; 2018 Oct; 142(10):1202-1215. PubMed ID: 30281371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]